Cat. #153208
HCT 116-I6 Invasive Cell Line
Cat. #: 153208
Sub-type: Continuous
Unit size: 1x10^6 cells / vial
Organism: Human
Tissue: Colon
Disease: Cancer
Model: Cancer Model
£575.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Inventor: Sandra Van Schaeybroeck
Institute: Queen's University Belfast
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: HCT 116-I6 Invasive Cell Line
- Cancer: Digestive / Gastrointestinal cancer
- Cancers detailed: Colorectal
- Research fields: Cancer;Cell biology;Drug development
- Tool sub type: Continuous
- Parental cell: HCT 116
- Organism: Human
- Tissue: Colon
- Disease: Cancer
- Growth properties: Invasion, migration
- Model: Cancer Model
- Conditional: No
- Description: The HCT 116-I6 cell line is a sub-line of HCT 116 that demonstrates a 4- and 20-fold increase in migration and invasion rate respectively compared to the parental cell line.
- Production details: HCT 116 cells were incubated in a Matrigel Invasion Chambers (MIC) for 72-96h. The cells that invaded through to the bottom chamber were collected and designated as ÄË?Â?ÂInvasive 1ÄË?Â? (I1). These cells were propagated and repeatedly passed through the MIC until highly invasive HCT116-I6 cells were selected.
- Cellosaurus id: CVCL_HG06
Handling
- Format: Frozen
- Growth medium: McCoy's 5a Medium (GIBCO # 16600) + 10% FBS + 100 units/ml penicillin+ 100 ?g/ml streptomycin
- Unit size: 1x10^6 cells / vial
- Shipping conditions: Dry ice
References
- Dunne et al. 2016. Clin Cancer Res. 22(1):230-42. PMID: 26283684.
- EphA2 Expression Is a Key Driver of Migration and Invasion and a Poor Prognostic Marker in Colorectal Cancer.
- Dunne et al. 2014. Clin Cancer Res. 20(1):164-75. PMID: 24170546.
- AXL is a key regulator of inherent and chemotherapy-induced invasion and predicts a poor clinical outcome in early-stage colon cancer.
